Cargando…
Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
BACKGROUND: Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i...
Autores principales: | Real, Jordi, Vlacho, Bogdan, Ortega, Emilio, Vallés, Joan Antoni, Mata-Cases, Manel, Castelblanco, Esmeralda, Wittbrodt, Eric T., Fenici, Peter, Kosiborod, Mikhail, Mauricio, Dídac, Franch-Nadal, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272340/ https://www.ncbi.nlm.nih.gov/pubmed/34243779 http://dx.doi.org/10.1186/s12933-021-01323-5 |
Ejemplares similares
-
Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia
por: Franch-Nadal, Josep, et al.
Publicado: (2019) -
Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007–2018
por: Mata-Cases, Manel, et al.
Publicado: (2022) -
Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia
por: Giménez-Pérez, Gabriel, et al.
Publicado: (2023) -
Clinical Characteristics and Degree of Glycemic and Cardiovascular Risk Factor Control in Patients with Type 1 Diabetes in Catalonia (Spain)
por: Gimenez-Perez, Gabriel, et al.
Publicado: (2021) -
Potential Risk of Overtreatment in Patients with Type 2 Diabetes Aged 75 Years or Older: Data from a Population Database in Catalonia, Spain
por: Mata-Cases, Manel, et al.
Publicado: (2022)